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Abstract 
Background: Treatment decisions on critically ill patients with circulatory shock lack consensus. In an international 
survey, we aimed to evaluate the indications, current practice, and therapeutic goals of inotrope therapy in the treat‑
ment of patients with circulatory shock.
Methods: From November 2016 to April 2017, an anonymous web‑based survey on the use of cardiovascular drugs 
was accessible to members of the European Society of Intensive Care Medicine (ESICM). A total of 14 questions 
focused on the profile of respondents, the triggering factors, first‑line choice, dosing, timing, targets, additional treat‑
ment strategy, and suggested effect of inotropes. In addition, a group of 42 international ESICM experts was asked to 
formulate recommendations for the use of inotropes based on 11 questions.
Results: A total of 839 physicians from 82 countries responded. Dobutamine was the first‑line inotrope in critically 
ill patients with acute heart failure for 84% of respondents. Two‑thirds of respondents (66%) stated to use inotropes 
when there were persistent clinical signs of hypoperfusion or persistent hyperlactatemia despite a supposed ade‑
quate use of fluids and vasopressors, with (44%) or without (22%) the context of low left ventricular ejection fraction. 
Nearly half (44%) of respondents stated an adequate cardiac output as target for inotropic treatment. The experts 
agreed on 11 strong recommendations, all of which were based on excellent (> 90%) or good (81–90%) agreement. 
Recommendations include the indications for inotropes (septic and cardiogenic shock), the choice of drugs (dobu‑
tamine, not dopamine), the triggers (low cardiac output and clinical signs of hypoperfusion) and targets (adequate 
cardiac output) and stopping criteria (adverse effects and clinical improvement).
Conclusion: Inotrope use in critically ill patients is quite heterogeneous as self‑reported by individual caregivers. 
Eleven strong recommendations on the indications, choice, triggers and targets for the use of inotropes are given by 
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Background
Circulatory shock affects about one-third of patients 
admitted to the intensive care unit (ICU) [1]. Shock 
is defined as insufficient oxygen and energy supply to 
organs and is associated with increased mortality [1, 2]. 
Traditionally, four types of circulatory shock have been 
distinguished by pathophysiological mechanisms, namely 
hypovolemic, cardiogenic, distributive and obstructive 
shock [3]. Critically ill patients present with one or a 
combination of these four types of circulatory failure [4].
Treatment of circulatory shock relies on timely initia-
tion of adequate fluid resuscitation combined with the 
use of vasoactive medication to restore tissue perfusion 
[5, 6]. Despite these therapeutic measures, cardiac out-
put (CO) is often inadequate to deliver enough oxygen to 
tissues in patients with circulatory shock [7]. Inotropes 
might improve CO and organ perfusion in patients with 
circulatory shock [8, 9]. Several guidelines for differ-
ent types of circulatory shock give different recommen-
dations for the use of inotropes [10–13]. Despite these 
different recommendations and the apparent lack of evi-
dence, inotropes are used in daily practice [13, 14]. Data 
on how inotropes are used in clinical practice are sparse 
[15]. Individual registries, observational studies, and tri-
als with patients in shock provide insight into the current 
standard of care. For example, in patients with cardio-
genic shock, vasopressors and inotropes were adminis-
tered in 94%, where dobutamine (49%) and levosimendan 
(24%) were the most commonly used inotropes [16]. 
For levosimendan, two systematic reviews with meta-
analyses and three large randomized trials have shown 
neutral effects on various outcomes [17–21], while one 
trial reported a possibility of harm (lower likelihood of 
successful weaning from mechanical ventilation and a 
higher risk of supraventricular tachyarrhythmia)[22]. A 
recent Cochrane review underlines the low quality of evi-
dence on the use of inotropes in cardiogenic shock with 
levosimendan showing a short-term survival benefit over 
dobutamine, while this benefit vanished on long-term 
follow-up [23]. In other types of shock, use of inotropes 
is less common. Some patients with septic shock may 
have improved tissue perfusion with inotropic therapy 
aimed at increasing oxygen delivery and in this situation, 
dobutamine is the first-line inotrope [8, 24]. However, a 
recent network meta-analysis suggests that levosimendan 
has the highest probability of being the best treatment 
in septic shock [25]. Yet, no large randomized trials 
have provided evidence for a mortality benefit of levosi-
mendan over dobutamine in septic shock [26].
Hence, further studies are needed on optimal treat-
ment with inotropes in circulatory shock states. To aid 
the design and interpretation of future studies on ino-
tropes, it is imperative to evaluate current practice and 
therapeutic goals of inotropic treatment of shock states 
to establish what is considered standard of care. The aim 
of the present study was to establish an overall picture of 
the standard of care, which was identified from a survey 
among members of the European Society of Intensive 
Care Medicine (ESICM). Furthermore, we developed 
recommendations on the use of inotropes based on a 
subsequent questionnaire and consensus finding by 
international experts in the field.
Methods
Survey development
Survey questions and response options were developed 
by the leadership of the Cardiovascular Dynamics Sec-
tion of ESICM. The survey consisted of 27 questions on 
the use of vasoactive drugs. The first results on the cur-
rent use of vasopressors in septic shock were recently 
published [6]. The present study focused on 14 survey 
questions related to the use of inotropes in circulatory 
shock. These questions concerned triggering factors, 
first-line drug choice, dosing, timing, targets, additional 
treatment strategies, and effects of inotropes.
The Research Committee of the ESICM endorsed the 
survey. Data were collected automatically using Survey-
Monkey Inc. (www.surve ymonk ey.com).
The survey was announced on the ESICM website and 
was open for participation between November 2016 and 
April 2017. Members of the Cardiovascular Dynamics 
section of the ESICM were additionally encouraged to 
participate via an email linking to the survey sent to email 
addresses in ESICM’s membership database in Novem-
ber 2016 with two subsequent e-mail reminders in Feb-
ruary 2017 and March 2017. No incentives were offered 
for participation. No personal information was collected, 
and no log-in was required to participate. Completing 
the internal consistency of items was enforced by display-
ing an alert before the questionnaire could be submitted 
and highlighting mandatory but unanswered questions. It 
international experts. Future studies should focus on consistent indications for inotrope use and implementation into 
a guideline for circulatory shock that encompasses individualized targets and outcomes.
Keywords: Acute circulatory failure, Sepsis, Septic shock, Cardiogenic shock, Resuscitation, Inotropes, Vasoactive 
agents, Catecholamines, Levosimendan, PDE‑inhibitors, Cardiac output
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was not possible to review and change the given answers 
after submission.
Survey reporting
The questionnaire’s methodology and results are 
reported according to the Checklist for Reporting Results 
of Internet E-Surveys (CHERRIES) statement [27]. Ethi-
cal approval for this study was not requested, as no iden-
tifying data were collected and consent was assumed by 
participating in the survey.
Experts’ recommendations
Based on the results of the ESICM members’ survey, 
three authors (TWLS, IVDH and JLT) identified areas 
of interest and developed 11 questions, including sub-
questions and approached a group of 42 experts, who 
are active members of the Cardiovascular Dynamics 
(CD) section of the ESICM. These experts have all pub-
lished research as first or last author in an international 
peer-reviewed journal in articles identified by the Pub-
Med subject headings “inotrope”, and they were asked to 
answer the developed experts’ questionnaire in order to 
summarize overall recommendations for the use of ino-
tropes in circulatory shock based on the ESICM mem-
bers’ survey and the experts’ questionnaire.
Definitions of the degree of consensus and grades of 
recommendations were based on the RAND algorithm 
[28]. Excellent agreement (> 90% agreement) and good 
agreement (81–90% agreement) were considered as 
strong grades of recommendation. A weak agreement 
was defined when 70–80% of the experts agreed. A Del-
phi-like process was used to achieve these consensus 
grades.
Statistics
Data were evaluated as the total distribution of single 
answers. Answers to the questionnaire items are reported 
as numbers (percentage). Contingency tables and corre-
sponding Chi-square statistics were reported to describe 
the pairwise associations between selected demographic 
variables (European vs. non-European ESICM member, 
high-income vs. lower-income countries, ICU experi-
ence more vs. less than 5  years full time, intensive care 
as primary specialty vs. other specialties, and university 
hospital vs. non-university hospital) and the responses 
regarding inotrope use. The nature of each question’s 
five answer options and their distribution prospectively 
defined the answer categories for the subsequent con-
tingency tables analyses (2 × 2). In two cases, only three 
(question 3) and two (question 7) answer options were 
used two define the two answer categories for contin-
gency tables. We used the World Bank definition of a 
“high-income country,” i.e., a per capita gross national 
income of $12,056 or more [29]. P < 0.05 was considered 
statistically significant. P-values are reported with their 
exact value for interpretation and not corrected for mul-
tiple testing in this descriptive reporting.
Results
Survey respondents’ characteristics
A total of 839 physicians from 82 countries participated 
in the survey. A firm estimate of response rate could not 
be calculated as the invitation to the survey was posted 
as an open link on the ESICM website. In addition, mem-
bers of the CD section of the ESICM (n = 10,780 at the 
time of the survey) received an email invitation to par-
ticipate. From these addressees, 3111 (29%) opened this 
e-mail (according to Mail Chimp). This corresponds to a 
response rate of 27% (839/3111) of those who opened the 
e-mail. Baseline demographic data of respondents and 
their ICU and hospitals are presented in Additional file 1: 
Table S1 [6].
Survey results
All seven questions and answers of the respondents 
on inotrope use in circulatory shock are summarized 
in Table  1. Dobutamine was reported to be used as the 
first-line inotrope in 704 (84%) of questionnaire respond-
ents, followed by PDE-inhibitors (7%), levosimendan 
(5%), dopamine (4%), and dopexamine (0.1%), while epi-
nephrine was not among the first 5 most used agents. 
First-line use of dobutamine was more common among 
non-Europeans than Europeans (88% vs. 82%, p = 0.049).
According to respondents, most inotropes are used 
when there are persistent clinical signs of hypoperfusion 
(e.g., skin mottling, low urine output) or persistent hyper-
lactatemia despite a supposed adequate use of fluids and 
vasopressors (65%) (Table 1).
Mostly, an adequate CO was the preferred target for 
inotropic treatment (44%) (Table 1).
The reasons for adding another inotrope when the 
patient did not respond to the first-line inotropic therapy 
varied among respondents (Table 1).
Most respondents preferred the combination of norepi-
nephrine plus dobutamine over epinephrine as preferred 
catecholamine in the treatment of circulatory shock 
(Table 1).
Concerning the use of phosphodiesterase (PDE)-
inhibitors, respondents employed by a university hospi-
tal and more experienced respondents were more likely 
to support PDE-inhibitors in right heart failure than 
non-university or less experienced respondents (52% vs. 
37%, p < 0.001 and 48% vs. 39%, p = 0.01, respectively) 
(Table 1).
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What is your first‑line inotrope to increase cardiac pump function?
 Dobutamine 706 84%
 Dopamine 37 4%
 Dopexamine 1 0.1%
 Levosimendan 38 5%
 Milrinone or any other phosphodiesterase inhibitor 57 7%
What are your most important criteria for using an inotrope to increase cardiac pump function?
 I measure CO and find it low (e.g., cardiac index < 2.5 L  min−1 m−2) 189 23%
 I measure central venous oxygen saturation and find it low (< 70%) 47 6%
 I measure left ventricular ejection fraction and find it low (< 45%) 54 6%
 There are persistent clinical signs of hypoperfusion (e.g., skin mottling, low urine output) or persistent hyperlactatemia 
despite a supposed adequate use of fluids and vasopressors
184 22%
 There are persistent clinical signs of hypoperfusion (e.g., skin mottling, low urine output) or persistent hyperlactatemia 
despite a supposed adequate use of fluids and vasopressors in the context of low left ventricular ejection fraction
365 44%
What are your primary therapeutic targets when using an inotrope?
 A normal lactate level 155 18%
 A normal veno‑arterial  PCO2 difference (< 6 mmHg) 37 4%
 An adequate CO 372 44%
 An adequate  ScvO2 173 21%
 An adequate urine output 102 12%
When the patient does not respond to your current inotropic therapy, what is your main reason for adding another inotrope/vasoactive agent to the 
current therapy?
 Although the maximum dose of the 1st choice inotrope has not been reached, previous increases in the inotrope dose 
were ineffective
129 15%
 By adding a second inotrope although the maximum dose of the 1st choice inotrope has not been reached, I want to 
limit/reduce the side effects of the first inotrope
193 23%
 I suppose that the mechanism of action of the first inotrope is exhausted (e.g., adrenoceptors down regulation) and 
want to use a second one with an independent mechanism of action
195 23%
 I want to use synergistic effects of two different mechanisms of action 233 28%
 The maximum dose of the 1st choice inotrope has been reached 89 11%
Which of the following statements fits best your opinion on catecholamine use in the treatment of shock?
 Although epinephrine (EPI) has the same adrenoceptors profile than the combination norepinephrine (NOR) plus dobu‑
tamine (DOB), the combination NOR plus DOB should be preferred since either component can be titrated individually
372 44%
 Although EPI has the same adrenoceptors profile than the combination NOR plus DOB, EPI should be preferred because 
of its easiness to be used (single agent)
50 6%
 The combination NOR plus DOB should be preferred over EPI due to a better patient outcome 95 11%
 The combination NOR plus DOB should be preferred over EPI since EPI may decrease regional blood flow, particularly in 
the splanchnic circulation
131 16%
 The combination NOR plus DOB should be preferred over EPI since EPI may increase blood lactate levels and cause 
cardiac arrhythmias
191 23%
Which of the following statements fit(s) best your opinion on the use of phosphodiesterase (PDE)‑inhibitors in the critically ill?
 Because of their prominent vasodilatory effect on the pulmonary circulation, PDE‑inhibitors should be preferred in the 
treatment of predominant right heart failure
365 43%
 Compared to pure vasodilators (e.g., nitroprusside), PDE‑inhibitors cause larger increases in CO and smaller decreases in 
arterial pressure
191 23%
 Compared to ß‑adrenoceptor agonists (e.g., dobutamine), PDE‑inhibitors have similar effects on CO but additionally 
decrease the cardiac filling pressures (CVP, PAOP)
162 19%
 PDE‑inhibitors should be avoided in the treatment of cardiogenic shock since they are associated with increased mortal‑
ity
74 9%
 PDE‑inhibitors should be avoided in the treatment of cardiogenic shock since they may increase the incidence of atrial 
fibrillation or tachyarrhythmias
47 6%
Which of the following statements fits best your opinion on the use of levosimendan in the critically ill?
 Levosimendan is the only inotrope that does not increase myocardial oxygen demand 354 42%
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Responses to the use of levosimendan varied among 
respondents, with experienced clinicians more likely 
selecting levosimendan than less experienced clinicians 
(61% vs. 52%, p = 0.01) (Table 1).
Experts’ questionnaire results
Forty-two selected experts gave their recommendations 
for clinical use of inotropes by responding to the expert-
opinion questionnaire (Fig. 1), and 40 of them replied to a 
follow-up questionnaire (Table 2).
Experts achieved excellent agreement (95%) on the 
statements that inotropes may be indicated in cardio-
genic shock, that inotropes are not indicated in hypov-
olemic shock, that dobutamine but not dopamine can 
be used for treating circulatory shock in clinical practice, 
that a low CO can be used as a trigger for starting ino-
tropic treatment, that clinical signs of hypoperfusion can 
be used as a target for inotropic treatment, and to lower 
or stop inotropic dosing, if patients experience unaccep-
table side effects. Other recommendations did not reach 
excellent agreement and for some the level of agreement 
was weak.
In general, experts individually stated that a recom-
mended trigger for inotropic treatment should also be a 
target for the treatment (see Table 3). An exception was 
LVEF, where 14 of the 24 experts, who did use low LVEF 
as a trigger for inotropic treatment, did not consider 
LVEF as a target for the treatment, and three of the 18 
experts, who did not choose low LVEF as a trigger did 
recommend using LVEF as a target for the treatment 
(Table 4).
Discussion
According to the results of this international survey, pref-
erences around the use of inotropes differ among physi-
cians. Most physicians (84%) chose dobutamine as their 
first-line inotrope, and dopamine, levosimendan, and 
milrinone (or another PDE-inhibitor) were considered 
first-line in up to 5% of respondents for patients with 
circulatory shock. Furthermore, the reasons for using 
an inotropic agent were diverse. Also, the variation in 
the primary therapeutic target was diverse, where CO, 
 ScvO2, lactate level and urine output were all well-repre-
sented answers among the respondents. Furthermore, the 
reasons for adding a vasopressor/inotrope if the patient 
did not respond to the inotropic agent administered to 
the patient were virtually uniformly distributed among 
the respondents, underscoring that balancing maximal 
doses, side effects, possible synergistic drug effects, etc., 
is challenging for clinicians in late/critical stages of circu-
latory shock.
The heterogeneous choices of physicians when it comes 
to inotropes may have various reasons. First, no solid 
evidence is available to support choosing one agent over 
another [12]. Recently, meta-analyses showed that for 
many inotropes evidence to support benefit is absent or 
weak [17, 18, 30]. Moreover, even a statistically signifi-
cant effect should still be interpreted with caution since 
the effects might be small and the clinical relevance 
uncertain. Second, the evidence is sparse and not robust, 
not only because of between-trial heterogeneity, but 
also because of high within-trial patient heterogeneity, 
combined with little or no individualization in the treat-
ment protocols. In turn, an effect of an inotrope might 
be present for certain (groups of ) patients equalized by 
harm of the same inotrope in other (groups of ) patients 
in the same trial [31]. As part of patient heterogeneity, 
the underlying pathophysiology and its impact on hemo-
dynamics may be incompletely understood and there-
fore, choosing the right agent might be difficult. Third, 
the optimal therapeutic targets for individual patients or 
groups of patients are unknown. More data have recently 
become available supporting different targets in different 
patients, an example being blood pressure [32]. Further-
more, specific targets for a variable such as CO or car-
diac index might be suboptimal. For one patient, a CO of 
3.0 L  min−1 might be sufficient to maintain organ perfu-
sion, for another patient, this level of CO might be asso-
ciated with organ hypoperfusion and organ dysfunction. 
Clearly, bedside titration of inotropes, based on individ-
ual patient responses, seems the most rational approach, 
but defining what those resuscitation targets should be, 
remains difficult. Finally, despite being available for many 
years (except for levosimendan in some countries), the 
optimal use of inotropes is incompletely understood, par-
ticularly beyond the choice of the first-line agent. Opti-
mal treatment concepts for timing, dosing, interaction, 






 Levosimendan is also a potent vasodilator in the systemic and pulmonary circulation 269 32%
 Levosimendan is associated with an increased incidence of atrial fibrillation and ventricular ectopy 83 10%
 Levosimendan is the only inotrope that is not associated with an increased mortality 55 7%
 Levosimendan may be considered as cardioprotective, as it reduces troponin I release (pleiotropic effect) 78 9%
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Fig. 1 Expert answers to the first questionnaire and level of agreement. Answers are visualized as percentages. Positive answers are presented in 
green, conditional answers are presented in yellow, negative answers are presented in red. PDE phosphodiesterase, v-a PCO2 veno‑arterial  PCO2 
difference, GoR grade of recommendation
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Standard of care or daily practice is obviously not 
uniform among the respondents. Solid meta-analyses 
of all inotropes, performed according to contemporary 
standards and taking into account bias from funding 
sources, should become available and updated if new 
evidence arises [17, 30]. Outcome measures should be 
uniformly defined and incorporate patient-centred out-
comes and not limited to surrogate outcomes such as 
CO. Therefore, triggers and goals/targets for treatment 
should be optimized by interpreting evidence of studies 
on hemodynamic monitoring.
Although primarily being a vasopressor, norepineph-
rine (in combination with dobutamine) was considered 
a preferred catecholamine for the treatment of circu-
latory shock. Even among experts there was disagree-
ment on whether norepinephrine should be considered 
a pure vasoconstrictor or an agent with combined vaso-
pressor and inotropic effects. Actually, through beta-1 
Table 2 Second round questionnaire to 40 experts on inotrope use
Question Answer
In a terminological sense (when discussing with fellow colleagues and/or researchers), do you refer to norepinephrine as a vasopressor?
 Exclusively a vasopressor 65%
 It is context dependent and not a fixed term in discussions with fellow colleagues and/or researchers 35%
In your physiological understanding and your treatment approach, do you consider norepinephrine:
 Exclusively a vasopressor (i.e., you only use it to modify blood pressure) 42%
 A vasopressor and an inotrope (i.e., in your treatment strategy, you consider it a drug to efficiently modify both blood pressure and cardiac 
output)
57%






Do you recommend a PDE‑inhibitor in right ventricular failure?
 Yes 65%
 No 35%
Table 3 Summary of consensus among experts and the degree of recommendations
Degree of consensus Grade 
of recommendation
Inotrope indications
 1. Inotropes are indicated in septic shock Good Strong
 2. Inotropes are indicated in cardiogenic shock Excellent Strong
 3. Inotropes are NOT indicated in hypovolemic shock Excellent Strong
Choice of inotrope
 4. Dobutamine is the first‑line inotrope Good Strong
 5. Dopamine is NOT a recommended inotrope Excellent Strong
Triggers
 6. Low cardiac output is a trigger for inotropic treatment Excellent Strong
 7. Signs of hypoperfusion are a trigger for inotropic treatment Good Strong
Targets
 8. Low cardiac output is a target for inotropic treatment Good Strong
 9. Signs of hypoperfusion are a target for inotropic treatment Excellent Strong
Dosing should be lowered or stopped when
 10. Patients experience unacceptable side effects Excellent Strong
 11. Patients show clinical improvement Good Strong
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adrenergic receptor stimulation, norepinephrine has 
been shown to increase systemic and microcircula-
tory blood flow along with blood pressure and preload 
in patients with septic shock [33–36]. Some clinicians 
might think of norepinephrine and also epinephrine 
as pure vasopressors because of their most dominant 
physiological effect, whereas others see it as a vasopres-
sor with clinically relevant inotropic effects that may 
be enough to support contractility as a single agent. 
The difficult to target inotropic effect (these agents are 
titrated primarily based on their vasopressor effect) and 
their potential arrhythmogenic effects at high doses 
should be taken into account when these agents are 
Table 4 Answers from 42 experts on questions Q5 and Q6 from Fig. 1, where the view on triggers and targets for inotropic 
use are combined. Conditional answers for Q5 in triggers (marked yellow in Fig. 1) are not represented in this table. There 
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used in this context. Epinephrine was hardly cited, pos-
sibly due to studies indicating safety concerns [37, 38].
Another interesting result is that most experts recom-
mended using more than one inotropic agent in the same 
patient. Reasons for this might be synergistic effects by 
adding an independent mechanism of action, e.g., in case 
of adrenoceptor downregulation, or the wish to limit the 
dose and side effects of each agent [6].
The majority of the respondents of the survey as well 
as the experts chose dobutamine as preferred inotrope in 
patients with hypoperfusion to increase CO, which is in 
accordance with current guidelines [8, 9, 24]. More evi-
dence might come from the ongoing ADAPT multicenter 
trial (ClinicalTrials.gov  ID: NCT04166331), which tests 
the hypothesis that dobutamine will reduce tissue hypop-
erfusion and associated organ dysfunctions in patients 
with septic shock and associated septic cardiomyopathy.
Since clinicians prefer having recommendations 
accompanying evidence summaries in the context of low 
certainty of evidence [39], we asked international experts 
in the field to draft and agree on recommendations 
regarding inotropic treatment. In general, experts agreed 
that a recommended trigger for starting inotropic treat-
ment should also be a therapeutic target, except for LVEF. 
Less than half of the experts using LVEF as a trigger for 
the use of an inotrope, also considered LVEF as the tar-
get for this use. This might be due to LVEF not being a 
continuously available variable, and its value is consid-
ered less reliable since it is mostly based on rough estima-
tion of echocardiographic images (eyeballing) rather than 
exact measurements in clinical practice.
In view of the lack of evidence on the use of inotropes 
in circulatory shock, we suggest the following research 
agenda for the coming years:
1. Determine univocal and personalized triggers and 
targets to start inotrope therapy in circulatory shock 
states.
 Current evidence and expert opinion differ on the 
initial triggers to start and then guide inotrope ther-
apy as targets in patients with circulatory shock. 
Consensus needs to be established on which triggers 
and target endpoints to use, ideally based on data 
rather than on expert opinion alone. These could be 
macro-hemodynamic values (e.g., cardiac output), 
surrogates of regional (organ) blood flow, or micro-
circulatory values (tissue perfusion, peripheral circu-
lation) [40].
 As an example, interventional trials have used vari-
ous triggers to initiate inotropic therapy such as 
“shock”, “low ejection fraction”, “low cardiac index” or 
“low  SvO2 not responding to fluids”. Also, some trials 
use a fixed dose while others attempt to reach a given 
value of cardiac index or  SvO2 or an improvement in 
a given variable (lactate, capillary refill time, micro-
circulation variables, etc.). It should be determined 
whether these triggers and targets should be identi-
cal for all patients or individualized based on cardiac 
function, organ perfusion, and underlying patient 
condition establishing an individualized benefit/risk 
profile.
2. Determine pharmacokinetics and pharmacodynam-
ics of inotropes in shock.
 Little is known about the pharmacokinetics and 
pharmacodynamics (e.g., clearance) of available 
inotropes in the presence of shock. Information on 
clearance and uptake of inotropes in shock may have 
implications for specific aspects related to the timing 
of interventions, the weaning of these drugs, limiting 
the risk of delayed hemodynamic failure or rebound 
effects. This might also include research on the con-
comitant use of other medication (e.g., beta-blockers) 
and the effects of the various inotropes on the host 
(inflammatory or immune) response [41]. Finally, 
the  individual variation in responses to inotropic 
drugs related to genetic related alterations in recep-
tors and/or signaling pathways should be evaluated.
3. Compare and combine available inotropic agents and 
identify new, safer inotropes.
 Further multicenter randomized controlled trials 
(with adaptive designs) are needed to compare dif-
ferent inotropic agents (a vs. b) and their combina-
tions (a + b vs. a or b alone) on different outcomes 
such as organ function, adverse effects and survival. 
For instance, combining two inotropic agents acting 
through different mechanisms or receptors (e.g., dob-
utamine + levosimendan) could permit minimizing 
the doses of each drug, thus reducing the incidence 
of adverse effects and increasing safety. The choice 
of combination should be based on the pharmaco-
logic properties of the different agents (see point 2). 
New, non-catecholamine inotropic agents that are 
not associated with side effects such as arrhythmia or 
hypotension should be identified and tested.
4. Combine inotrope therapy with personalized care 
bundle.
 While inotrope use needs to be personalized in 
future research, the other mainstays of circulatory 
shock treatment must be employed in a similar per-
sonalized manner to improve comparability. For 
instance, optimal MAP targets in circulatory shock 
and the role of fluid therapy should ideally be estab-
lished as these will influence inotrope therapy. How-
ever, this in itself will be challenging as there is no 
current consensus on types of fluid, monitoring and 
other interventions being delivered, nor on how to 
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adopt an optimal personalized approach. For exam-
ple, a one-size-fits-all approach for MAP targets can-
not be optimal.
5. Develop and implement core outcome sets for 
patients with circulatory shock.
 Core outcome sets (i.e., standardized collection of 
outcomes measured and reported in all trials for a 
specific clinical area) should be developed for circu-
latory shock research due to established inconsisten-
cies in trial outcome selection. Any new trial assess-
ing the benefit/risk of inotropes should include the 
selection of an adequately targeted study population 
to improve the “noise/signal ratio” inherent to heter-
ogeneous cohorts (in terms of hemodynamic profile).
6. Evaluate the impact of prolonged (> 72  h) inotropic 
therapy on myocardial energetics.
 Experimental and clinical data on inotrope use dem-
onstrate direct effects of inotropes on myocardial 
injury, energetics and modulation of the immune/
inflammatory response. The relevance of this to fur-
ther organ injury and patient outcomes needs to be 
established. Data from experimental and clinical 
studies in chronic heart failure suggest that long-term 
inotropic therapy leads to interstitial calcinosis, myo-
cardial fibrosis and contraction band necrosis [42]. 
Does this also apply to the context of shock where 
the duration of inotropic stimulation is expected 
to be shorter (less than one month)? What is the 
maximal duration of intravenous inotropic therapy 
before receptor down regulation, diastolic dysfunc-
tion, myocardial injury, and persistent arrhythmias 
develop in this setting?
7. Establish specific use of inotropes in patients under 
mechanical circulatory support.
 The use of inotropic agents should be adapted in 
patients under mechanical circulatory support for 
cardiogenic shock secondary to acute myocardial 
infarction. When are these agents indicated in this 
specific setting, and which hemodynamic targets 
should be used? The purpose of inotropic stimulation 
and the choice and doses of the inotropic agent may 
not be identical at the initiation of mechanical cir-
culatory support, during the maintenance phase, or 
during the weaning process.
8. Evaluate the best hemodynamic strategy in predomi-
nant right ventricular failure.
 In patients with circulatory shock, which is predomi-
nantly associated with right ventricular failure, the 
question should be answered by comparative effec-
tiveness trials if inotropic agents or vasopressors 
(e.g., norepinephrine to increase coronary perfusion 
pressure) should be preferred.
9. Better define the interaction between IV fluids and 
vasoactive agents.
 The physiologic interplay between vasoactive agents 
and intravenous fluids is evident, but the scientific 
evidence in terms of comparative effectiveness tri-
als (fluids vs. early vasopressor use, addition of ino-
tropes, etc.) is scarce. For instance, inotropic agents 
can only increase myocardial contractility, lusitropy, 
and heart rate. They do not primarily increase car-
diac output. For cardiac output to increase there 
also needs to be sufficient blood volume and vas-
cular tone, as known from the poor impact of ino-
tropic agents in hemorrhagic shock and profound 
vasoplegia. Therefore, the optimal vasopressor/fluid/
inotrope ratio remains to be determined at the indi-
vidual level.
Ongoing and upcoming studies such as ADAPT 
(NCT04166331: Effects of dobutamine on tissue hypop-
erfusion and associated organ dysfunctions in patients 
with septic shock and associated septic cardiomyopathy) 
and LevoHeartShock (NCT04020263: Early use of levosi-
mendan versus placebo on top of conventional inotropes 
in patients with cardiogenic shock) will probably provide 
important answers to some of these questions.
Limitations
The number of responses is considered high (correspond-
ing to 27% of ESICM members who opened the e-mail 
invite), but the methods used to invite individuals to 
respond did not allow us to report a conclusive response 
rate. Therefore, response bias might be present, in which 
case, external validity could be somewhat hampered.
The results presented in this manuscript come from 
an online survey. Online surveys have limitations like 
potential multiple responses by a single person. We did 
not use cookies or log-file/IP address analyses to prevent 
multiple responses. On the other hand, individual per-
sons are unlikely to spend time answering a survey more 
than once. Another limitation is the multiple-choice 
character of our survey, limiting answers to those offered. 
In addition, studies published after the survey was per-
formed [38, 43–46] might have altered the answers of 
the respondents. Nevertheless, after careful analysis of 
the results of those studies we believe that the experts’ 
recommendation would not have changed significantly. 
Furthermore, the recommendations of experts can only 
reach excellent agreement if the available evidence is 
solid and clear. The evidence for inotropes in circulatory 
shock lack this evidence for many questions raised. Fur-
thermore, both patients and studies show high heteroge-
neity. Therefore, recommendations should be interpreted 
with caution.
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Conclusions
In conclusion, the use of inotropes in critically ill 
patients is quite heterogeneous as reported by indi-
vidual caregivers. International experts recommend 
the use of inotropes in septic and cardiogenic shock 
(but not in hypovolemia), using an inadequate CO and 
signs of tissue hypoperfusion as triggers and targets for 
treatment, and adverse effects and clinical improve-
ment as stopping/weaning criteria. While experts rec-
ommend using dobutamine as the first-line agent, they 
recommend against the use of dopamine. Future stud-
ies reporting patient-centred outcomes should focus 
on specific subpopulations based on prespecified and 
measurable triggers, targets, and with clear stopping 
criteria in order to ensure comparability across trials. 
This would allow a better summary of the evidence and 
its implementation in future guidelines.
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